S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot
S&P 500   5,137.08
DOW   39,087.38
QQQ   445.61
Lawyers who successfully argued Musk pay package was illegal seek $5.6 billion in Tesla stock
Critical asset just had biggest fall on record (Ad)
Sports analytics may be outnumbered when it comes to artificial intelligence
In Senegal's capital, Nicaragua is a hot ticket among travel agents as migrants try to reach US
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
Norway's hospitalized king gets a pacemaker in Malaysia after falling ill during vacation
Head Start preschools aim to fight poverty, but their teachers struggle to make ends meet
This is the #1 Stock to Buy for the AI Tidal Wave (Ad)
What to watch for as China's major political meeting of the year gets underway
Chicago 'mansion' tax to fund homeless services stuck in legal limbo while on the ballot

BioNexus Gene Lab (BGLC) Competitors

$0.72
+0.15 (+26.55%)
(As of 03/1/2024 ET)

BGLC vs. PMD, OPGN, CNTG, XGN, AKUMQ, DMTK, SRNE, NXGL, COSM, and LGVN

Should you be buying BioNexus Gene Lab stock or one of its competitors? The main competitors of BioNexus Gene Lab include Psychemedics (PMD), OpGen (OPGN), Centogene (CNTG), Exagen (XGN), Akumin (AKUMQ), DermTech (DMTK), Sorrento Therapeutics (SRNE), NEXGEL (NXGL), Cosmos Health (COSM), and Longeveron (LGVN). These companies are all part of the "medical" sector.

BioNexus Gene Lab vs.

BioNexus Gene Lab (NASDAQ:BGLC) and Psychemedics (NASDAQ:PMD) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their earnings, profitability, dividends, valuation, community ranking, media sentiment, analyst recommendations, institutional ownership and risk.

24.1% of Psychemedics shares are held by institutional investors. 24.0% of Psychemedics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

BioNexus Gene Lab has higher earnings, but lower revenue than Psychemedics. BioNexus Gene Lab is trading at a lower price-to-earnings ratio than Psychemedics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
BioNexus Gene Lab$10.93M1.16-$360K-$0.02-35.75
Psychemedics$22.80M0.79-$1.08M-$0.68-4.59

Psychemedics received 142 more outperform votes than BioNexus Gene Lab when rated by MarketBeat users.

CompanyUnderperformOutperform
BioNexus Gene LabN/AN/A
PsychemedicsOutperform Votes
142
74.35%
Underperform Votes
49
25.65%

Psychemedics has a net margin of -16.69% compared to BioNexus Gene Lab's net margin of -29.92%. Psychemedics' return on equity of -40.62% beat BioNexus Gene Lab's return on equity.

Company Net Margins Return on Equity Return on Assets
BioNexus Gene Lab-29.92% -42.85% -34.09%
Psychemedics -16.69%-40.62%-22.68%

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
BioNexus Gene Lab
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
Psychemedics
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A

In the previous week, BioNexus Gene Lab had 2 more articles in the media than Psychemedics. MarketBeat recorded 3 mentions for BioNexus Gene Lab and 1 mentions for Psychemedics. Psychemedics' average media sentiment score of 0.93 beat BioNexus Gene Lab's score of 0.30 indicating that Psychemedics is being referred to more favorably in the news media.

Company Overall Sentiment
BioNexus Gene Lab Neutral
Psychemedics Positive

Summary

Psychemedics beats BioNexus Gene Lab on 9 of the 13 factors compared between the two stocks.


Get BioNexus Gene Lab News Delivered to You Automatically

Sign up to receive the latest news and ratings for BGLC and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BGLC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BGLC vs. The Competition

MetricBioNexus Gene LabMedical laboratories IndustryMedical SectorNASDAQ Exchange
Market Cap$12.63M$1.89B$5.21B$7.62B
Dividend YieldN/A1.81%2.82%3.87%
P/E Ratio-35.758.19257.1618.81
Price / Sales1.16157.613,095.74110.41
Price / CashN/A382.8799.8655.35
Price / BookN/A2.754.534.54
Net Income-$360,000.00-$122.90M$114.95M$211.55M
7 Day Performance5.13%2.64%5.71%3.36%
1 Month Performance62.50%8.30%11.26%6.68%
1 Year PerformanceN/A-13.82%13.49%8.85%

BioNexus Gene Lab Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
PMD
Psychemedics
0 of 5 stars
$3.09
-0.3%
N/A-43.7%$17.93M$22.80M-4.54133News Coverage
OPGN
OpGen
0.4371 of 5 stars
$0.46
+9.4%
N/A-44.9%$4.65M$2.61M-0.0785Short Interest ↑
Gap Down
CNTG
Centogene
4.1131 of 5 stars
$0.93
+1.1%
$1.50
+61.3%
-36.4%$25.18M$50.03M0.00444News Coverage
Gap Down
XGN
Exagen
4.888 of 5 stars
$1.95
-4.9%
$5.50
+182.1%
-20.8%$33.25M$45.56M-1.05199Short Interest ↓
News Coverage
AKUMQ
Akumin
0 of 5 stars
$0.38
-6.3%
N/AN/A$34.19M$749.63M-0.133,631Gap Down
DMTK
DermTech
1.1677 of 5 stars
$1.31
+3.1%
$5.50
+319.8%
-78.9%$44.85M$14.52M-0.37278Analyst Revision
News Coverage
Gap Down
SRNE
Sorrento Therapeutics
0.5445 of 5 stars
$0.03
-71.4%
N/A-91.2%$13.21M$60.32M0.00799Gap Up
NXGL
NEXGEL
0 of 5 stars
$2.29
-2.6%
N/A+77.1%$13.10M$2.05M-4.7712Positive News
Gap Down
COSM
Cosmos Health
1.1014 of 5 stars
$0.77
+1.3%
N/A-76.1%$13.04M$49.59M0.00102Short Interest ↑
LGVN
Longeveron
3.1658 of 5 stars
$0.54
+3.8%
$9.25
+1,613.0%
-85.1%$13.56M$1.22M-0.5519Short Interest ↓
Analyst Revision
News Coverage

Related Companies and Tools

This page (NASDAQ:BGLC) was last updated on 3/2/2024 by MarketBeat.com Staff